Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Piramal Pharma Limited (PPLPHARMA.NS)
Mumbai, MH, IN
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; offers inhalation anesthetics, intrathecal therapy, injectable pain and anesthesia drugs, and other generic and specialty products; and analgesics, skin care, vitamin/mineral supplement, kids’ wellness, digestives, women’s health, and hygiene, as well as adult incontinence. The company was incorporated in 2020 and is based in Mumbai, India.
Based on only 1 article — low confidence
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.33% | +0.83% | +8.09% | +10.12% | -4.55% | +3.86% | -12.87% | +121.86% | -3.61% | -3.61% | -3.61% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-2.1% Q1'26: +3.3% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-461.8% Q1'26: -106.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+1.4% Q1'26: +16.6% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+1.0% Q1'26: +8.8% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+0.7% Q1'26: +4.7% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-1.1% ★ Q1'26: -4.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×6.16× Q1'26: 3.08× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 10 Rev. Ana. 6 EPS Ana. |
Mar 2027 11 Rev. Ana. 9 EPS Ana. |
Mar 2028 11 Rev. Ana. 9 EPS Ana. |
Mar 2029 5 Rev. Ana. 4 EPS Ana. |
Mar 2030 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
70.32B
est: 70.82B (-0.7%)
|
81.06B
est: 83.73B (-3.2%)
|
90.61B
est: 92.75B (-2.3%)
|
88.64B
87.07B – 92.81B
-4.4% YoY
|
100.55B
96.03B – 102.41B
+13.4% YoY
|
114.92B
107.38B – 123.74B
+14.3% YoY
|
127.93B
127.72B – 128.14B
+11.3% YoY
|
141.36B
133.45B – 148.38B
+10.5% YoY
|
| EBITDA |
8.94B
est: 12.08B (-25.9%)
|
13.67B
est: 13.00B (+5.1%)
|
16.49B
est: 14.40B (+14.5%)
|
13.76B
13.52B – 14.41B
-4.4% YoY
|
15.61B
14.91B – 15.90B
+13.4% YoY
|
17.84B
16.67B – 19.21B
+14.3% YoY
|
19.86B
19.83B – 19.90B
+11.3% YoY
|
21.95B
20.72B – 23.04B
+10.5% YoY
|
| EBIT |
2.18B
est: 5.98B (-63.6%)
|
6.26B
est: 5.26B (+18.9%)
|
8.33B
est: 5.83B (+42.8%)
|
5.57B
5.47B – 5.84B
-4.4% YoY
|
6.32B
6.04B – 6.44B
+13.4% YoY
|
7.23B
6.75B – 7.78B
+14.3% YoY
|
8.04B
8.03B – 8.06B
+11.3% YoY
|
8.89B
8.39B – 9.33B
+10.5% YoY
|
| Net Income |
-1.86B
est: 1.70B (-209.6%)
|
178.20M
est: 277.60M (-35.8%)
|
911.30M
est: 1.69B (-46.0%)
|
-555.61M
-1.94B – 833.41M
-132.9% YoY
|
1.80B
1.08B – 3.11B
+424.4% YoY
|
5.29B
2.74B – 7.84B
+193.8% YoY
|
10.28B
8.40B – 12.16B
+94.2% YoY
|
14.97B
13.88B – 15.94B
+45.6% YoY
|
| SGA |
21.05B
est: 7.14B (+194.9%)
|
22.03B
est: 22.66B (-2.8%)
|
25.17B
est: 25.10B (+0.3%)
|
23.98B
23.56B – 25.11B
-4.4% YoY
|
27.21B
25.98B – 27.71B
+13.4% YoY
|
31.09B
29.06B – 33.48B
+14.3% YoY
|
34.62B
34.56B – 34.67B
+11.3% YoY
|
38.25B
36.11B – 40.15B
+10.5% YoY
|
| EPS |
-1.54
est: 1.27 (-221.3%)
|
0.14
est: 0.21 (-34.1%)
|
0.69
est: 1.28 (-46.1%)
|
-1.00
-1.47 – 0.63
-177.9% YoY
|
1.41
0.82 – 2.35
+241.5% YoY
|
4.07
2.07 – 5.92
+188.5% YoY
|
7.56
6.34 – 9.18
+85.8% YoY
|
11.30
10.48 – 12.03
+49.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-25 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-22 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-21 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-20 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-19 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-18 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-15 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-14 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-13 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-12 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-11 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.03% | 3.94M | 0.06% |
| 2 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.01% | 292.9K | 0.26% |
| 3 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.01% | 129.8K | 0.48% |
| 4 | Vanguard FTSE Emerging Markets ETF VWO | 0.01% | 14.45M | 0.06% |
| 5 | Vanguard ESG International Stock ETF VSGX | 0.00% | 189.3K | 0.10% |
| 6 | Vanguard Total International Stock ETF VXUS | 0.00% | 15.76M | 0.05% |
| 7 | Vanguard ESG Global All Cap UCITS ETF (USD) Accumulating V3AA.L | 0.00% | 22.2K | 0.24% |
| 8 | Vanguard ESG Global All Cap UCITS ETF (USD) Distributing V3AL.L | 0.00% | 22.2K | 0.24% |
| 9 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 23.2K | 0.22% |
| 10 | Vanguard Total World Stock ETF VT | 0.00% | 828.3K | 0.06% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Debashish Chakravorty | Executive Vice President of India & UK Formulations | — | male |
| Gagan Borana | Head of Investor Relations & Sustainability | — | male |
| Maneesh Sharma | Company Secretary & Compliance Officer | — | male |
| Nandini Ajay Piramal | Executive Chairperson | — | female |
| Peter DeYoung | Chief Executive Officer of Piramal Global Pharma & Director | — | male |
| Prashanth S. | Vice President of Sales | — | — |
| Pratibha Mishra | Interim Company Secretary & Compliance Officer | — | female |
| Puneet Rajput | Chief Human Resources Officer | — | female |
| Sandeep K. Rathod | General Counsel | — | male |
| Vinay Agarwal | Senior Vice President of Operations | — | — |
| Viral Gandhi | President & Group Chief Information Officer of Piramal Group | — | male |
| Vivek Valsaraj | Chief Financial Officer & Executive Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PPLPHARMA.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
